The Trusted Real-World Companion over a decade
Now At an Amazing Price
₹ 12.95/-
₹ 9.50/-
₹ 14.50/-
Real world experience in India for over 11 years
>3 L Patients living well with diabetes
Available at >10 L chemist across India
Best-in-class efficacy, safety & hassle-free experience
Help your patients to live well with Diabetes by revisiting the evidence
Better Efficacy with dosage convenience compared to Vildagliptin
Superior DPP4 inhibition
Siltagliptin 100 mg OD 91.7%
(Cl 91.4, 92.1)
Vildagliptin 50 mg OD 28.9%
(Cl 17.9, 38.4)
Recommended BID dose of Vildagliptin offers
just 90.6% DPP4 inhibition.
Proven CV Safety and Hepatic Safety compared to Vildagliptin
| Parameter | Istavel/ Istamet | Azathioprine |
|---|---|---|
| Prospective CVOT | TECOS | No prospective CVOT |
| Primary Outcome | No increased risk of hospitalization due to HF; CV-related death; Nonfatal stroke; Nonfatal MI | |
| Use in NYHA Class | Safe and effective in all NYHA class | Inconclusive results in NYHA class II patients and not recommended in NYHA class IV patients |
| Use in Hepatic Impatient | Can be used in mild to moderate Hepatic Impairment | Not recommended in patients with Hepatic impairment including patients with a pre-treatment ALT or AST > 2.5 X the upper limit of normal |
Newly diagnosed type 2 diabetes mellitus: Indian Experts Consensus
- Majority of newly diagnosed Indian diabetics have HbA1C >7.5%.
- Patients with HbA1C >7.5% may be initiated with dual therapy of dipeptidyl peptidase 4 inhibitors (DPP4Is) + Metformin.
- In Indian patients with HbA1C >7.5% at diagnosis, DPP4Is + Metformin may be considered as a first line therapy.
